| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Eugenol — Eugenol is a naturally occurring phenylpropanoid and volatile aromatic phenol most strongly associated with clove oil from Syzygium aromaticum. Eugenol is a phenolic aromatic ingredient that is chiefly derived from clove oil. It is formally classified as a small-molecule phytochemical, essential-oil constituent, food-flavouring agent, and experimental anticancer adjunct rather than an approved oncology drug. Standard abbreviations include EUG and 4-allyl-2-methoxyphenol. It is also present in cinnamon, basil, bay, nutmeg, and other aromatic plants. The oncology evidence is mainly preclinical, with strongest support for apoptosis induction, PI3K/Akt suppression, anti-metastatic effects, and chemo/radiosensitization in cell and animal models. clove oil has been advertised as a dental pain-relieving agent and germicide, and is used in mouthwashes and pharmaceutical drugs. Eugenol (4-allyl (-2-mthoxyphenol)), a phenolic natural compound available in honey and in the essential oils of different spices such as Syzgium aromaticum (clove), Pimenta racemosa (bay leaves), and Cinnamomum verum (cinnamon leaf). Primary mechanisms (ranked):
Bioavailability / PK relevance: Eugenol is rapidly absorbed and extensively metabolized, mainly through conjugation pathways, so systemic exposure is transient and formulation-dependent. Its volatility, lipophilicity, rapid metabolism, and local irritation risk make delivery strategy important. Nanoemulsions, encapsulation, and conjugated delivery systems are being explored preclinically to improve stability, exposure, and tumour delivery. In-vitro vs systemic exposure relevance: Many in-vitro anticancer studies use micromolar-to-high-micromolar concentrations that may exceed freely achievable systemic exposure after ordinary dietary or flavouring-level intake. Low-dose mechanistic reports exist in some breast cancer models, but translation remains uncertain. Essential-oil or clove-derived exposure should not be equated with purified eugenol pharmacology because source composition, dose, and route strongly affect exposure. Clinical evidence status: Preclinical. Eugenol has cell-line and animal-model anticancer evidence, plus limited adjunctive clinical-context use in aromatherapy or topical/dental products, but there is no established clinical evidence supporting eugenol as a cancer treatment. Registry-visible oncology studies involving essential oils generally assess symptom support or mixtures, not purified eugenol as an anticancer therapeutic. Eugenol Cancer Mechanism Table
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| In all eukaryotic cells, intracellular Ca2+ levels are maintained at low resting concentrations (approximately 100 nM) by the activity of the major Ca2+ extrusion system, the plasma membrane Ca2+-ATPase (PMCA), which exchanges extracellular protons (H+) for cytosolic Ca2+. Indeed, sustained elevation of [Ca2+]C in the form of overload, saturating all Ca2+-dependent effectors, prolonged decrease in [Ca2+]ER, causing ER stress response, and high [Ca2+]M, inducing mitochondrial permeability transition (MPT), are considered to be pro-death factors. In cancer the Ca2+-handling toolkit undergoes profound remodelling (figure 1) to favour activation of Ca2+-dependent transcription factors, such as the nuclear factor of activated T cells (NFAT), c-Myc, c-Jun, c-Fos that promote hypertrophic growth via induction of the expression of the G1 and G1/S phase transition cyclins (D and E) and associated cyclin-dependent kinases (CDK4 and CDK2). Thus, cancer cells may evade apoptosis through decreasing calcium influx into the cytoplasm. This can be achieved by either downregulation of the expression of plasma membrane Ca2+-permeable ion channels or by reducing the effectiveness of the signalling pathways that activate these channels. Such protective measures would largely diminish the possibility of Ca2+ overload in response to pro-apoptotic stimuli, thereby impairing the effectiveness of mitochondrial and cytoplasmic apoptotic pathways. Voltage-Gated Calcium Channels (VGCCs): Overexpression of VGCCs has been associated with increased tumor growth and metastasis in various cancers, including breast and prostate cancer. Store-Operated Calcium Entry (SOCE): SOCE mechanisms, such as STIM1 and ORAI1, are often upregulated in cancer cells, contributing to enhanced cell survival and proliferation. High intracellular calcium levels are associated with increased cell proliferation and migration, leading to a poorer prognosis. Calcium signaling can also influence hormone receptor status, affecting treatment responses. Increased Ca²⁺ signaling is associated with advanced disease and metastasis. Patients with higher CaSR expression may have a worse prognosis due to enhanced tumor growth and resistance to apoptosis. -Ca2+ is an important regulator of the electric charge distribution of bio-membranes. |
| 6330- | Eug, | Molecular Mechanisms of Action of Eugenol in Cancer: Recent Trends and Advancement |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:399 Target#:38 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid